Table 6. Various agents in evaluation to treat NASH in Humans (www. Clinicaltrials.gov).
| Agent | Nature of the Study |
|---|---|
| Metformin vs. Vit E vs. Placebo (TONIC) | Phase III, multicenter, RCT |
| Pioglitazone vs. Metformin vs. placebo (PIVENS) | Phase III, multicenter, RCT |
| Omega-3 fatty acids | Phase II, pilot study |
| Polyunsaturated fatty acids | Phase II, pilot study |
| Orlistat | Phase III, multicenter study |
| Silophus | Phase II, pilot study |
| Silymarin | Phase II, multicenter RCT |
| Rimonabant | Phase IIb, multicenter RCT |
| Recombinant leptin | Phase II, pilot study |
| Pentoxiphylline | Phase II, pilot study |
| Pentoxiphylline vs. Pioglitazone | Phase II, pilot study |
| Exendatide | Phase II, pilot study |
| Rosi vs.Rosi + metformin vs. rosi + losartan | Phase III, single center |
| SAMe | Phase II, pilot study |
| Iron depletion | Phase II, pilot study |
| CP 945598 | Phase IIb, multicenter RCT |
| TRO 19622† | Phase II, pilot study |
| ASP9831Ψ | Phase II, pilot study |
| L-Alanine | Phase II, pilot study |
†
Cholesterol like small molecule and is a potent neuroprotective agent in-vitro. May have mitochondrial protective effects
Ψ
Novel PDE4 inhibitor which may be improve hepatic inflammation and fibrosis